



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 3351

Exploration of the active site of β 4GalT7: modifications of the aglycon of aromatic xylosides[†]

Anna Siegbahn,^{‡a} Karin Thorsheim,^{‡a} Jonas Ståhle,^b Sophie Manner,^a Christoffer Hamark,^b Andrea Persson,^c Emil Tykesson,^c Katrin Mani,^c Gunilla Westergren-Thorsson,^c Göran Widmalm^b and Ulf Ellervik^{*a}

Proteoglycans (PGs) are macromolecules that consist of long linear polysaccharides, glycosaminoglycan (GAG) chains, covalently attached to a core protein by the carbohydrate xylose. The biosynthesis of GAG chains is initiated by xylosylation of the core protein followed by galactosylation by the galactosyltransferase β 4GalT7. Some β -D-xylosides, such as 2-naphthyl β -D-xylopyranoside, can induce GAG synthesis by serving as acceptor substrates for β 4GalT7 and by that also compete with the GAG synthesis on core proteins. Here we present structure–activity relationships for β 4GalT7 and xylosides with modifications of the aromatic aglycon, using enzymatic assays, cell studies, and molecular docking simulations. The results show that the aglycons reside on the outside of the active site of the enzyme and that quite bulky aglycons are accepted. By separating the aromatic aglycon from the xylose moiety by linkers, a trend towards increased galactosylation with increased linker length is observed. The galactosylation is influenced by the identity and position of substituents in the aromatic framework, and generally, only xylosides with β -glycosidic linkages function as good substrates for β 4GalT7. We also show that the galactosylation ability of a xyloside is increased by replacing the anomeric oxygen with sulfur, but decreased by replacing it with carbon. Finally, we propose that reaction kinetics of galactosylation by β 4GalT7 is dependent on subtle differences in orientation of the xylose moiety.

Received 19th December 2014,
Accepted 28th January 2015

DOI: 10.1039/c4ob02632b

www.rsc.org/obc

1 Introduction

Proteoglycans (PGs) are highly anionic macromolecules that consist of one or several long linear polysaccharides, glycosaminoglycan chains (GAGs), covalently attached to a core protein. Two classes of GAG chains, chondroitin sulfate (CS)/dermatan sulfate (DS) and heparin/heparan sulfate (HS), are linked to the core protein by the carbohydrate xylose. The biosynthesis of these are initiated by xylosylation of the core protein by xylosyltransferases (XT). Two galactose residues are then added stepwise to the xylosylated protein by two different galactosyltransferases, β 4GalT7 (GalT-I)¹ and β 3GalT6

(GalT-II),² followed by addition of one glucuronic acid unit, by a glucuronyltransferase (GlcAT-I), to form a tetrasaccharide linker, *i.e.* GlcA(β 1–3)Gal(β 1–3)Gal(β 1–4)Xyl β -PG (Fig. 1a). This linker is then polymerized from repeating disaccharide units. Furthermore, during and after the polymerization of the GAG chains, modifications, such as epimerization, O- and N-sulfation, and N-deacetylation, result in an extensive structural diversity of the GAG chains.

β -D-Xylosides, such as 2-naphthyl β -D-xylopyranoside (**1**, XylNap), serve as substrates for β 4GalT7 and can thereby initiate formation of soluble GAG chains (Fig. 1b), and at the

^aCenter for Analysis and Synthesis, Center for Chemistry and Chemical Engineering, Lund University, P.O. Box 124, SE-221 00 Lund, Sweden.
E-mail: ulf.ellervik@chem.lu.se

^bDepartment of Organic Chemistry, Arrhenius Laboratory, Stockholm University, SE-106 91 Stockholm, Sweden

^cDepartment of Experimental Medical Science, Lund University, BMC, SE-221 00 Lund, Sweden

[†]Electronic supplementary information (ESI) available: ¹H-NMR, ¹³C-NMR, MS of disaccharides from β 4GalT7 assay. See DOI: 10.1039/c4ob02632b

[‡]These authors contributed equally to this work.




Fig. 1 (a) Biosynthesis of the linker tetrasaccharide of HS and CS/DS PGs. (b) Galactosylation of XylNap to form GalXylNap.






Chart 1 Investigated glycosides.

same time compete with GAG synthesis on core proteins forming PGs.

All enzymes that are known to be involved in the biosynthesis of the tetrasaccharide linker have been cloned,³ and we have recently reported assays for measurement of galactosylation by, and inhibition of, the enzyme β4GalT7.⁴ We investigated the structure–activity relationships for modifications of the xylose moiety and found that the binding pocket of β4GalT7 is narrow, with a precise set of important hydrogen bonds. We have also shown that xylose appears to be the optimal acceptor substrate for galactosylation by the enzyme and that modifications on the xylose moiety of the β-D-xylopyranosides instead can render inhibitors of galactosylation.

The biological functions of PGs are mainly due to interactions of GAG chains with different protein ligands and regulatory factors, which make them important for several normal cellular processes, but also for cancer growth, invasion, and metastasis.⁵ A possible therapeutic strategy may thus be to target key enzymes in the GAG biosynthesis. For example, tumor growth has been blocked by treatment of a HSPG-inhibiting xyloside in combination with an inhibitor of the formation of polyamines,⁶ and we have earlier shown xyloside-induced, selective inhibition of the growth of tumor cells *in vitro* as well as *in vivo*.^{7,8}

We envision that inhibitors of β4GalT7 will be valuable tools for the exploration of GAG biosynthesis and a starting point for development of anti-tumor agents. Galactosyltransferase inhibitors are often based on donor substrate analogs, *i.e.* UDP-Gal.⁹ By instead using inhibitors based on the acceptor substrate, in this case xylose, an increased selectivity can be obtained. To broaden the knowledge of the structural requirements for β4GalT7, we now present data for modifications of the aglycon according to Chart 1.


In our recent study⁴ we also observed strong inhibition of β4GalT7 by 2-naphthyl α-L-arabinoside, a xyloside analog epimerized at position 4. Thus, in addition to xylosides, we have included arabinosides to investigate inhibition of β4GalT7.

2 Results

2.1 Synthesis

Compounds **1**,¹⁰ **2**,¹¹ **9**,¹² **12–15**,¹³ **16**,⁷ **17**,¹⁴ **18**,¹⁵ **21**,¹⁶ and **22**¹⁷ have been reported previously, and compounds **2** and **20** are commercially available. Compounds **3**, **4**, **5**, and **7** have been published before,¹⁰ however, full physical characterization has not been reported, hence, the syntheses and the analyses are described herein. The majority of the xylosides were synthesized through glycosylation of peracetylated β-D-xylopyranose **27** with different aromatic aglycons (phenol, 1-naphthol, 4-phenylphenol, 6-cyano-2-naphthol, and 2-naphthalenethiol) in CH₂Cl₂ with BF₃·Et₂O and Et₃N (Scheme 1). The naphthyl thioxyloside **32** was smoothly oxidized to the corresponding β-linked sulfone **33** in excellent yield using *m*CPBA. To form the α-anomer of **1**, the glycosylation reaction was performed in MeCN with BF₃·Et₂O and 2-naphthol without addition of Et₃N. Subsequent de-O-acetylation using standard Zemplén conditions generated **3**, **4**, **5**, **7**, **8**, **11**, and **19** in good yields. 2-Naphthyl β-L-xylopyranoside **10** was synthesized according to the method described above for the xylosides with β-linkage, starting from peracetylated β-L-xylopyranose **34** (Scheme 1). (9-Anthracene)-methyl xyloside **6** could not be synthesized from peracetylated xylose **27**, but was instead synthesized from peracetylated β-xylosyl bromide **36** *via* a Koenigs–Knorr reaction using Ag₂O followed by standard Zemplén deprotection (Scheme 1).





Scheme 1 Reagents and conditions: (i) BF₃·Et₂O, 1-naphthol, Et₃N, CH₂Cl₂; BF₃·Et₂O, 4-phenylphenol, Et₃N, CH₂Cl₂; BF₃·Et₂O, 6-cyano-2-naphthol, Et₃N, CH₂Cl₂; BF₃·Et₂O, 2-naphthalenethiol, CH₂Cl₂; BF₃·Et₂O, 2-naphthol, Et₃N, CH₂Cl₂; (ii) NaOMe (1 M), MeOH; (iii) mCPBA, CH₂Cl₂, (iv) BF₃·Et₂O, 2-naphthol, MeCN; (v) 9-anthracenemethanol, Ag₂O, 4 Å MS, CH₂Cl₂; (vi) 2-naphthalenethiol, TBAHS, Na₂CO₃ (1 M), EtOAc; (vii) 2-naphthalenemethanol, Ag₂O, 4 Å MS, CH₂Cl₂; (viii) KOAc, Ac₂O; (ix) BF₃·Et₂O, 2-(2-chloroethoxy)-ethanol, CH₂Cl₂; (x) 2-naphthol, K₂CO₃, 18-crown-6, DMF, 80 °C.

Peracetylated β-arabinopyranosyl bromide **37**¹⁸ was used as starting point for the synthesis of arabinosides. Phase transfer catalysis, a mild procedure with excellent anomeric stereo-selectivity, was used to synthesize naphthyl thioarabinoside **38** (Scheme 1). To obtain the arabinosyl sulfone **24**, thioarabinoside **38** was oxidized using the same procedure as for compound **8**, generating the desired sulfone in 96% yield. Using arabinosyl bromide **37** as a donor in a Koenigs–Knorr reaction with 2-naphthalenemethanol, in the presence of Ag₂O, generated **40**. Deacetylation of **38–40** yielded the corresponding arabinosides **23–25**, respectively. The Koenigs–Knorr glycosylation reaction could also be used for the synthesis of **26**. However, the route *via* peracetylated L-arabinose increased the yield of

42 from 13% to 30%, calculated from L-arabinose **41** (Scheme 1). Thus, acetylation of L-arabinose **41** with KOAc in Ac₂O generated an α/β-mixture (approximately 5.4 : 1), and glycosylation of that mixture with 2-(2-chloroethoxy)-ethanol in the presence of BF₃·Et₂O formed the arabinoside **42**. Treatment of **42** with 2-naphthol, K₂CO₃, and 18-crown-6 produced **43** in 40% and deacetylation generated arabinoside **26** in good yield.

2.2 β4GalT7 assay

We have expressed a truncated version of β4GalT7 fused with glutathione *S*-transferase in *E. coli* and used it in enzymatic assays to measure the galactosylation by, and inhibition of, β4GalT7.⁴ To determine if the glycosides could serve as acceptor substrates for β4GalT7, various concentrations of the glycosides were incubated with the recombinant β4GalT7 and the donor substrate, UDP-Gal, for 30 minutes at 37 °C. The reaction progress was analyzed using HPLC with fluorescence detection. We found that none of the arabinosides served as substrate for β4GalT7 (data not shown), whereas all of the synthesized xylosides were galactosylated, except L-XylNap **10** and α-XylNap **11** (Table 1). The identities of galactosylated products were verified by LCMS analysis (ESI, Table S1†). The kinetic parameters, summarized in Table 1, were calculated using the nonlinear regression to the Michaelis–Menten model. We observed excess-substrate inhibition of the enzyme by **5–8**, **16**, and **18** (Fig. 2), at the studied substrate concentrations. For

Table 1 Galactosylation of xylosides by β4GalT7

Compound	K_m (mM)	V_{max} (pmol s ⁻¹)	k_{cat} (s ⁻¹)	k_{cat}/K_m (mM ⁻¹ s ⁻¹)
Part A: variation of aglycon size				
1 ^a	0.58	1.1	1.5	2.6
4	0.57	1.3	1.8	3.2
5 ^b	0.17	0.72	1.0	6.0
6 ^b	0.12	0.43	0.60	5.1
Part B: variation at the anomeric center or of absolute configuration				
1 ^a	0.58	1.1	1.5	2.6
7 ^b	0.25	1.7	2.3	9.4
8 ^b	0.066	1.7	2.4	37
9	2.4	1.8	2.5	1.0
10	—	—	—	—
11	—	—	—	—
Part C: variation of linker length				
1 ^a	0.77	1.2	1.7	2.2
12	0.48	1.9	2.6	5.5
13	0.60	2.0	2.7	4.6
14	0.091	0.93	1.3	14
15	0.24	2.4	3.3	13
Part D: variation of electronic properties				
1 ^a	0.58	1.1	1.5	2.6
16 ^b	0.58	1.6	2.2	3.8
17	0.31	1.2	1.6	5.2
18 ^b	0.31	1.1	1.5	4.8
19	0.60	2.0	2.8	4.7

^aThe assay was carried out with various batches of enzyme, and slightly different kinetic parameters for **1** were obtained. The compounds in each part were investigated with the same batch. Hence, comparisons can be made within the same part. ^b Apparent kinetic parameters were obtained for concentrations up to the highest observed reaction rate.






Fig. 2 Michaelis–Menten representation of the activity of $\beta 4\text{GalT7}$ (V) as a function of the concentration of compound **8**.

Table 2 Inhibition of GalXylNap formation by $\beta 4\text{GalT7}$; 0.5 mM XylNap and 2.0 mM of glycoside were added in the assay in each experiment. The decrease of formed GalXylNap in presence of glycoside is expressed in % of the amount GalXylNap formed without added glycoside

Compound	Inhibition (% of control)
Xylosides	
2	21 ± 13
3	44 ± 3
7	80 ± 0.3
8	93 ± 1
10	0
11	0
Arabinosides	
20	11 ± 3
21	28 ± 8
22	63 ± 5
23	22 ± 3
24	38 ± 3
25	0
26	10 ± 0.3

these compounds, the apparent kinetic parameters were calculated using the concentrations up to the highest observed reaction rate.

To determine the potential inhibitory effect of selected glycosides, XylNap, which is known to be a substrate for $\beta 4\text{GalT7}$, was used as a mimic of the natural substrate (*i.e.* the xylosylated core protein). A fixed amount of XylNap was added, together with different concentrations of glycosides, and the amount of formed GalXylNap was measured. A decrease in formation of GalXylNap, compared to control, indicates that the tested glycoside compete with XylNap for the binding site of $\beta 4\text{GalT7}$. The decrease in formation of GalXylNap, was used to indirectly determine the galactosylation efficiency of the methyl and phenyl xylosides (compounds **2** and **3**), since fluorescence could not be used for detection of these. As expected, compounds **2** and **3**, showed less decrease of galactosylation of XylNap, than, for example, compound **7** (Table 2). Several arabinose analogs were investigated and found to inhibit $\beta 4\text{GalT7}$

activity to various extents (Table 2), but none as efficiently as the previously reported compound **22**.

2.3 GAG priming in cells

Compound **8** showed the highest activity (k_{cat}/K_m) according to the $\beta 4\text{GalT7}$ assay (Table 1). To investigate if this result was transferable to the GAG priming ability in cell culture, the GAG priming of compound **8** in HCC70 cells was determined, using compound **1** and **7** as reference compounds.^{7,14} HCC70 cells were incubated with the xyloside analogs in low sulfate medium supplemented with [³⁵S]sulfate. After 24 h of incubation at 37 °C, [³⁵S]sulfate-labeled material was isolated from the culture media, separated based on size by HPLC, and the amount of radioactivity was measured to estimate the amount of GAG priming. Compounds **1** and **7** were found to initiate the formation of GAG priming to a similar extent, whereas compound **8** primed 3.4 times as much GAG chains as **1** (Fig. 3). This correlates well with data from the enzymatic assay.

2.4 Molecular docking simulations of the Michaelis complex

To gain further insight into the galactosylation reaction, the xyloside acceptor substrates **1**, **5**, **7**, **8**, and **12–15** were studied *in silico* in complex with $\beta 4\text{GalT7}$. Molecular docking simulations were performed with the Autodock VINA software and the acceptor ligands were docked to the protein in the closed conformation in the presence of a rigid UDP donor as well as manganese (based on coordinates from PDB IDs 4M4K and




Fig. 3 Xyloside-induced priming of GAG chains (approx. fractions 35–50) isolated from HCC70 cells. The cells were incubated with XylNap (**1**, solid grey line), **7** (dashed line), and **8** (dotted line) and secreted polyanionic material was subjected to size exclusion chromatography on a Superose 6 column. The solid black line shows the result for untreated cells.



4LW6). Dockings were performed in both presence and absence of water molecules¹⁹ in the crystal structure but it was concluded that additional insights were not gained when including water. In addition, protein interactions to the naphthyl moiety were hindered by water in the crystal structure. Thus, water molecules were excluded from the docking simulations.

An initial docking was performed with acceptor ligand **1** in presence of UDP in the donor site (PDB ID 4LW6). The nine highest ranked poses showed a non-uniform distribution of the ligand throughout the binding pocket of the protein, including several cases with the xylose residues positioned in the donor substrate site. These findings indicate that the acceptor substrate competes for this site. It also highlights the importance of a galactose residue to form the acceptor substrate binding site (*vide infra*). Subsequent dockings were performed to mimic the Michaelis complex, *i.e.* with UDP-galactose as the donor (PDB ID 4M4K). From the generated binding poses of the docked ligands (**1**, **5**, **7**, **8**, and **12–15**), a similar positioning of the xylose moiety was observed. The acceptor binding site is a shallow pocket, which is defined by acidic residues as well as the donor substrate. The pocket encloses xylose whereas the aglycon moiety extends from the binding site, interacting with the exterior of the enzyme, consisting mainly of aromatic residues (Fig. 4a and b).

One geometry optimized complex for each ligand, selected through cluster analyses of the docked poses, was analyzed in more detail. From these results we suggest that the xylose moiety is oriented in the binding site with a beneficial CH- π interaction between H5 and the aromatic ring of Y177. All xylo-side hydroxyl groups act as hydrogen bond donors, whereas O3 also acts as a hydrogen bond acceptor for L209. The hydrogen-bonding pattern changes, depending on the coupling to the aromatic moiety. For ligand **1** and the sulfone containing ligand **8**, the xylose moiety is tilted, compared to the other compounds, resulting in hydrogen bonds from both O2 and O3 to D212 and from O4 to N211 (Fig. 4b). Compounds **5**, **7**, and **12–15** show a more pronounced CH- π interaction from H5 to Y177 and O2, O3, and O4 hydrogen bond to D212, N211, and either O4 in UDP-Gal or N211, respectively (Fig. 4a). This latter orientation closely resembles that of xylobiose from the crystal structure.²⁰ Furthermore, the naphthyl group generally adopts a face-to-face stacking to the aromatic ring of Y179.

3 Discussion

We have synthesized a number of glycosides and investigated their interactions with β 4GalT7 using enzymatic assays, cell studies, and molecular docking simulations. From the computational studies, we observe that the acceptor binding site of β 4GalT7 is a shallow pocket enclosing the xylose moiety where the aglycon extends out to the surface of the enzyme. The xylo-side moiety displays only subtle differences in binding orientation between the different ligands. The naphthyl moiety tends to interact with a face-to-face π -stacking with Y179 on




Fig. 4 Active site region of β 4GalT7 mutant D211N complex with UDP-D-Gal, manganese and (a) ligand **12** or (b) ligand **8**. Residues W207, G208, K259, and R263 have been hidden to increase visibility of the active site.

the outside of the pocket. Apart from compounds **10** and **11**, all of the other studied xylosides (Chart 1) were galactosylated by β 4GalT7, and several of the studied xylosides showed substrate inhibition. Even if the mechanism for substrate inhibition is unclear, it is possible that it originates in substrate binding to the enzyme without binding of UDP-Gal. Furthermore, our molecular modeling indicates that the acceptor substrate competes for the same site as the donor substrates, suggesting that the acceptor may act as an inhibitor by binding to the β 4GalT7-UDP complex.

3.1 Part A: variation of aglycon size

Several xylosides carrying relatively small aglycons have shown GAG priming ability in earlier cell studies and enzymatic



assays. In an early study by Robinson *et al.*,²¹ it was shown that D-xylose initiated GAG priming to a small extent, whereas **2** was about four times, and **44** and **45** about twelve times, more efficient. In 1991, Lugemwa and Esko studied xylosides with different aglycon size.²² They found that xylosides carrying aromatic aglycons were more efficient GAG primers than aliphatic analogs. For example, GAG chains primed by **46**, were shown to incorporate 14 times more [³⁵S] sulfate compared to **47**. Later, Esko and co-workers²³ found that both **48** and **49** primed GAG chains in the same range as **46** and **1**. The disaccharide **50** did not initiate GAG synthesis but when three of the hydroxyl groups were methylated, the priming of GAG chains was comparable to that by **1**.²⁴ The natural product **51** was also found to initiate GAG synthesis.²⁵ In 2005, we synthesized compound **52**, a fluorescently labeled analog to **17**, which was taken up by cells but did not initiate priming of GAG chains.²⁶ Apart from O-linked xylosides with large aglycons, Kuberan and co-workers^{27,28} have made triazole-linked xylosides of which some primed GAG chains, like **53**, while others did not.

The results from our β 4GalT7 assay were in agreement with results from earlier investigations. According to the molecular modeling, there is a π - π interaction between the naphthyl moieties of **1** and **7** and the side-chain of Y179. It can be assumed that the π - π interaction between Y179 and phenyl xyloside **3** is weaker since the distance between the two residues is larger. Methyl xyloside **2**, lacking an aromatic aglycon, cannot interact in such a favorable manner.

Compounds **1** and **4**, which differ in the binding orientation of the naphthyl moiety, were galactosylated by β 4GalT7 to a similar extent, whereas compound **5**, with a biphenyl aglycon, showed a slightly increased galactosylation. These results correlate with the study by Esko and co-workers²³

where **1**, **4**, and **5** were found to initiate GAG synthesis. The kinetic parameters for galactosylation of **6** were similar to **5**. It is reasonable that the aglycon, which extends out of the binding pocket, provides stronger binding by favorable π - π interactions, but that the effect is limited and not favored by even larger aromatic moieties.


3.2 Part B: variation at the anomeric center or of absolute configuration

It has long been known that α -xylosides, such as **54**, **55**, **56**, and **57** (Chart 2), do not initiate GAG synthesis, and these compounds have therefore often been included in studies as negative controls.^{21,29-32} However, there are studies in which some GAG priming by α -xylosides have been observed, *e.g.* **56**³³ and some triazole-linked xylosides.³⁴


Xylosides with *S*-xylosidic bonds generally initiate GAG priming comparable to the corresponding *O*-xylosides.^{21,32,33,35} For example, we have earlier investigated a series of hydroxynaphthyl 1-thio- β -D-xylopyranosides that all showed strong priming of relatively short GAG chains.³⁶ *C*- and *N*-xylosides have been reported to be less efficient as GAG primers compared to the corresponding *O*- or *S*-xylosides.^{33,35,37} Kuberan and co-workers^{27,28,34,38-40} have made several series of amide- and triazole-linked xylosides of which the GAG priming ability varied with variations in the aglycon moiety.

As expected, the *L*-xyloside **10** and the α -xyloside **11** were not found to be galactosylated by β 4GalT7. The *C*-xyloside **9** was galactosylated to a significantly smaller extent than **1**, in contrast to the sulfur analog **7** that was galactosylated more efficiently. Interestingly, the sulfone analog **8** was found to be galactosylated by β 4GalT7 several times more efficiently than **1**. The very efficient galactosylation of **8** by β 4GalT7 was


Part A: Variation of aglycon size



Part B: Variation at the anomeric center or of absolute configuration



Part C: Variation of linker length



Part D: Variation of electronic properties




Chart 2 Discussed glycosides with various biological activities (literature data).






Fig. 5 GAG priming and galactosylation plotted against xylose–aglycon distance ($C1_{Xyl}-C2_{Nap}$). The proportion of GAG priming is given as the integrated value of fractions from cells treated with xyloside, divided by the integrated values for fractions from untreated cells.¹³ The xylose–aglycon distances are measured in nm from the anomeric carbon to the aromatic carbon coupled to the linker. Circles (blue) indicate GAG priming in CCD-1095Sk cells, diamonds (red) indicate GAG priming in HCC70 cells, and squares (black) indicate k_{cat}/K_m values (s^{-1} , mM^{-1}). Compound numbers in parenthesis.

accompanied by efficient priming of GAG chains in cell studies.

The relationship between the nucleophile and the electrophile in a chemical reaction has been shown to be highly dependent on the distance and angle between the nucleophile and the electrophile.⁴¹ In this case one may speculate that the reaction kinetics of galactosylation by $\beta 4GalT7$ is dependent on the orientation of O4 of the xylose moiety in relation to C1 of the galactose moiety, and that subtle differences in orientation might give rise to large effects in reaction efficiency.

3.3 Part C: variation of linker length

In 1994, Esko and co-workers²³ noted that the GAG priming ability was not affected when the distance between the xylose residue and the naphthyl moiety in XylNap was increased by a linker. It has also been reported that a triazole-linker, compound **58**, increased the GAG priming compared to **59**.²⁸

Recently, we made a systematic investigation of the effects of the xylose–aglycon distance on GAG priming ability.¹³ A series of xylosides, where the xylose residue was separated from the naphthyl aglycon with linkers of different lengths, was synthesized (compounds **12–15**), and the GAG priming abilities were investigated in cells. The results varied between different cell lines, but an enhancement of the GAG priming ability was generally observed when the xylose–naphthyl distance increased (Fig. 5).

In this study, the galactosylation of compounds **12–15** was investigated in the $\beta 4GalT7$ assay. There is a trend towards increased galactosylation with increased xylose–aglycon distance (Fig. 5). However, the galactosylation does not perfectly correlate with the GAG priming for either cancer cells or normal cells. This leads us to speculate that the amount of xyloside-induced GAG priming is influenced not only by the galactosylation ability of the corresponding xylosides, but also other factors. For example, differences between cancer cells and normal cells regarding xyloside uptake, intracellular transport, or glycosyltransferases in the GAG biosynthesis.

3.4 Part D: variation of electronic properties

p-Nitrophenyl β -D-xylopyranoside **61** was one of the first xylosides for which GAG priming ability was observed, and it has been used as a control in several cell studies and enzymatic studies.^{29,42–44} Xylosides with a carboxyl group attached to the aromatic ring in the aglycon have been observed to be less efficient as GAG primers compared to the corresponding methyl ester or non-substituted compound.^{15,32,35} In solution, these xylosides are most probably charged, which limit the uptake and the cellular transportation. Furthermore, all 14 possible hydroxynaphthyl β -D-xylopyranosides have been evaluated and were shown to initiate synthesis of GAG chains with different proportions of HS chains.⁴⁵ Moreover, the methoxy ether **16** was reported to initiate synthesis of GAG chains,⁷ and the methoxy ether of **62** was galactosylated in an enzymatic assay.⁴⁶

Since compound **17** has shown interesting properties, both in priming of GAG chains and in selective growth inhibition of tumor cells, we decided to investigate compounds modified in position 6 of the naphthyl moiety. Therefore, groups with electron donating or electron withdrawing properties were introduced in this position. The kinetic parameters for galactosylation by $\beta 4GalT7$ of these compounds were found to be in the same range. Hence, the electron density of the aromatic residue does not seem to affect the binding to the active site to any greater extent.

3.5 Part E: inhibitors

Finally, to investigate if the galactosylation efficiency can be used for design of inhibitors of $\beta 4GalT7$, we included a few arabinose analogs with various aglycons and investigated their ability to inhibit $\beta 4GalT7$ activity. However, we observed that the corresponding arabinoside of an efficiently galactosylated xyloside is not necessarily an efficient inhibitor. Since the inhibitors do not participate in the reaction, the inhibitory effects shown by the arabinosides obviously reflect other steps in the binding sequence and thus deviate from the trends shown for galactosylation substrates.

4 Conclusions

From structure–activity relationships combined with molecular docking simulations, we conclude that xylose should be conju-



gated to an aromatic aglycon in order to be efficiently galactosylated by β 4GalT7, and subsequently initiate GAG synthesis in cells. Since the aglycons reside on the outside of the active site of the enzyme, quite bulky aglycons seem to be accepted. Furthermore, the aromatic aglycon can be separated from the xylose moiety by linkers and retain, or increase, the amount of galactosylation. Generally, only xylosides with β -glycosidic linkages are good substrates for β 4GalT7. We also show that the galactosylation ability of a xyloside is increased by replacing the anomeric oxygen with sulfur, but decreased by replacing it with carbon. Substituents on the aromatic aglycon might alter the GAG priming ability depending on identity and position in the aromatic framework. Finally, we propose that reaction kinetics of galactosylation by β 4GalT7 is dependent on subtle differences in orientation of the xylose moiety. Thus, a good substrate for galactosylation is not necessarily a good starting point for design of inhibitors.

5 Experimental part

5.1 Synthesis

All moisture- and air-sensitive reactions were carried out under an atmosphere of dry nitrogen using oven-dried glassware. All solvents were dried prior to use unless otherwise stated. Purchased reagents were used without further purification. Organic phases were dried using Biotage ISOLUTE Phase separators. Chromatographic separations were performed on Matrex silica gel (25–70 μ m), or on a Biotage Isolera One flash purification system using Biotage SNAP KP-Sil silica cartridges. Thin-layer chromatography was performed on precoated TLC alumina plates coated with silica gel 60 F₂₅₄ 0.25 mm (Merck). Spots were visualized with UV light or by staining with *para*-anisaldehyde. NMR spectra were recorded at ambient temperatures with a Bruker Avance II 400 MHz spectrometer at 400 MHz (¹H) and at 100 MHz (¹³C). ¹H NMR spectra were assigned using COSY (2D homonuclear shift correlation) with a gradient selection and NOESY (nuclear Overhauser effect spectroscopy). Chemical shifts are given in ppm, with reference to residual internals CDCl₃ (δ 7.26), CD₃OD (δ 3.31), (CD₃)₂SO (δ 2.50), or C₆D₆ (δ 7.16). Coupling constant values are given in Hz. Mass spectra were recorded on Micromass Q-ToF microTM. Optical rotations were measured on Perkin Elmer instrument, Model 341 polarimeter and are given in 10⁻¹ deg cm² g⁻¹. A Waters 600 Series HPLC system equipped with a Waters Symmetry C₁₈ column (5 μ m, 19 \times 100 mm) was used for purification. Synthesis and physical characterization of compounds **1**,¹⁰ **2**,¹¹ **9**,¹² **12–15**,¹³ **16**,⁷ **17**,¹⁴ **18**,¹⁵ **21**,¹⁶ and **22**¹⁷ have been reported previously and compounds **2**, **20**, **27**, **28**, **34**, **36**, and **41** are commercially available.

5.1.1 Typical procedure for glycosylation using BF₃·Et₂O (method A). BF₃·OEt₂ (2.5 eq.) was added to a stirred solution of Et₃N (0.5 eq.), alcohol (1.5 eq.), and per-*O*-acetylated donor (1 eq.) in CH₂Cl₂ (0.2 M) at rt. After 6 h, satd aq. NaHCO₃ was added and the reaction mixture was extracted with CH₂Cl₂. The combined organic phases were dried before removal of

solvent under reduced pressure and the crude residues were purified with column chromatography using EtOAc–heptane, EtOAc–toluene, or Et₂O–petroleum ether as eluent.

5.1.2 Typical procedure for glycosylation using Ag₂O (method B). Ag₂O (1 eq.) was added to a stirred solution of bromide donor (1 eq.), alcohol (2 eq.), and 4 Å MS in CH₂Cl₂ (0.2 M) at 0 °C. After 1 h, the temperature was let to reach rt and the reaction mixture was stirred for 18 h before filtration through SiO₂ and removal of solvent under reduced pressure. The crude residues were purified with column chromatography using EtOAc–heptane as eluent.

5.1.3 Typical procedure for sulfone synthesis. *m*CPBA (4 eq.) was added in portions over 5 minutes to a stirred solution of thioglycoside (1 eq.) in CH₂Cl₂ (0.1 M) at 0 °C. After 2 hours, CH₂Cl₂ was added and the organic phase was washed with satd aq. NaHCO₃, brine, and water. The organic phase was dried before removal of solvent under reduced pressure and the crude residues were purified with column chromatography using EtOAc–heptane as eluent.

5.1.4 Typical procedure for de-*O*-acetylation (Zemplén conditions). Glycoside (1 eq.) was stirred in MeOH (0.3 M) containing NaOMe (0.05 M) at rt. After 4 h, glacial AcOH was added until neutral pH before removal of solvent under reduced pressure. The crude residues were purified with column chromatography using MeOH–CH₂Cl₂ as eluent.

5.1.4.1 Phenyl β -*D*-xylopyranoside (3). Compound **3** was obtained from **28** following the de-*O*-acetylation method as a white solid (94%). [α]_D²⁰ –51 (*c* 1, MeOH), ¹H-NMR (CD₃OD) δ 7.25–7.30 (m, 2H, ArH), 7.03–7.07 (m, 2H, ArH), 6.98–7.02 (m, 1H, ArH), 4.85–4.87 (m, 1H, H-1), 3.92 (dd, 1H, *J* 5.4, 11.4 Hz, H-5e), 3.55–3.61 (m, 1H, H-4), 3.40–3.47 (m, 2H, H-2, H-3), 3.35 (dd, 1H, *J* 10.4, 11.2 Hz, H-5a); ¹³C-NMR (CD₃OD) δ 158.9, 130.4, 123.4, 117.8, 102.8, 77.7, 74.7, 71.0, 66.9; HRMS calcd for C₁₁H₁₄O₅Na⁺ [*M* + Na]: 249.0733; found: 249.0736.

5.1.4.2 1-Naphthyl β -*D*-xylopyranoside (4). Compound **4** was obtained from **29** following the de-*O*-acetylation method as a white solid (69%). [α]_D²⁰ –73 (*c* 2, MeOH), ¹H-NMR (CD₃OD) δ 8.36–8.39 (m, 1H, ArH), 7.77–7.80 (m, 1H, ArH), 7.50 (d, 1H, *J* 8.4 Hz, ArH), 7.43–7.47 (m, 2H, ArH), 7.36 (t, 1H, *J* 8.0 Hz, ArH), 7.13 (d, 1H, *J* 8.0 Hz, ArH), 5.07 (d, 1H, *J* 7.6 Hz, H-1), 3.97 (dd, 1H, *J* 5.2, 11.6 Hz, H-5e), 3.63–3.69 (m, 2H, H-2, H-4), 3.51 (t, 1H, *J* 8.8 Hz, H-3), 3.40 (t, 1H, *J* 11.2 Hz, H-5a); ¹³C-NMR (CD₃OD) δ 154.5, 136.1, 128.4, 127.5, 127.3, 126.8, 126.3, 123.3, 123.1, 110.5, 103.3, 77.8, 74.9, 71.1, 67.0; HRMS calcd for C₁₅H₁₆O₅Na⁺ [*M* + Na]: 299.0895; found: 299.0895.

5.1.4.3 4-Phenylphenyl β -*D*-xylopyranoside (5). Compound **5** was obtained from **30** following the de-*O*-acetylation method as a white solid (88%). [α]_D²⁰ –21 (*c* 0.7, MeOH), ¹H-NMR (CD₃OD) δ 7.53–7.58 (m, 4H, ArH), 7.38–7.42 (m, 2H, ArH), 7.27–7.31 (m, 1H, ArH), 7.11–7.15 (m, 2H, ArH), 4.91 (d, 1H, *J* 7.2 Hz, H-1), 3.94 (dd, 1H, *J* 5.6, 11.6 Hz, H-5e), 3.58–3.62 (m, 1H, H-4), 3.43–3.48 (m, 2H, H-2, H-3), 3.38 (dd, 1H, *J* 10.2, 11.5 Hz, H-5a); ¹³C-NMR (CD₃OD) δ 158.5, 142.0, 136.8, 129.8, 129.0, 127.9, 127.7, 118.1, 102.9, 77.7, 74.8, 71.0, 67.0; HRMS calcd for C₁₇H₁₈O₅Na⁺ [*M* + Na]: 325.1052; found: 325.1052.



5.1.4.4 (9-Anthracene)-methyl β -D-xylopyranoside (6). Compound **6** was obtained from **36** using glycosylation method B followed by de-O-acetylation of crude (9-anthracene)-methyl 2,3,4-tri-O-acetyl β -D-xylopyranoside as a light yellow solid (2%). $[\alpha]_D^{20} -7$ (c 0.6, MeOH), $^1\text{H-NMR}$ (CD_3OD) δ 8.53 (s, 1H, ArH), 8.49 (d, 2H, J 8.8 Hz, ArH), 8.05 (d, 2H, J 8.4 Hz, ArH), 7.54–7.58 (m, 2H, ArH), 7.46–7.50 (m, 2H, ArH), 5.83 (d, 1H, J 11.2 Hz, CH_2Ar), 5.67 (d, 1H, J 11.2 Hz, CH_2Ar), 4.45 (d, 1H, J 7.6 Hz, H-1), 4.22 (dd, 1H, J 5.2, 11.2 Hz, H-5e), 3.49–3.60 (m, 1H, H-4), 3.20–3.29 (m, 3H, H-2, H-3, H-5a); $^{13}\text{C-NMR}$ (CD_3OD) δ 132.9, 132.6, 129.9, 129.6, 129.0, 127.3, 126.1, 125.6, 104.0, 77.9, 74.8, 71.3, 67.2, 63.8; HRMS calcd for $\text{C}_{20}\text{H}_{20}\text{O}_5\text{Na}^+$ $[\text{M} + \text{Na}]$: 363.1208; found: 363.1207.

5.1.4.5 2-Naphthyl 1-thio- β -D-xylopyranoside (7). Compound **7** was obtained from **32** following the de-O-acetylation method as a white solid (83%). $[\alpha]_D^{20} -50$ (c 0.7, MeOH), $^1\text{H-NMR}$ (CD_3OD) δ 8.01 (d, 1H, J 0.8 Hz, ArH), 7.79–7.84 (m, 2H, ArH), 7.80 (d, 1H, J 8.8 Hz, ArH), 7.59 (dd, 1H, J 1.6, 8.8 Hz, ArH), 7.45–7.51 (m, 2H, ArH), 4.67 (d, 1H, J 9.2 Hz, H-1), 3.97 (dd, 1H, J 4.8, 11.2 Hz, H-5e), 3.46–3.52 (m, 1H, H-4), 3.37 (t, 1H, J 8.4 Hz, H-3), 3.23–3.31 (m, 2H, H-2, H-5a); $^{13}\text{C-NMR}$ (CD_3OD) δ 135.1, 134.0, 132.2, 131.8, 130.5, 129.3, 128.7, 128.5, 127.6, 127.3, 90.0, 79.2, 73.8, 70.9, 70.5; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_4\text{SNa}^+$ $[\text{M} + \text{Na}]$: 315.0667; found: 315.0667.

5.1.4.6 2-Naphthyl β -D-xylopyranosyl sulfone (8). Compound **8** was obtained from **33** following the de-O-acetylation method as a white solid (69%). $[\alpha]_D^{21} -35$ (c 0.5, MeOH); $^1\text{H NMR}$ (CD_3OD): δ 8.54 (s, 1H, ArH), 8.07–8.11 (m, 2H, ArH), 8.02 (d, 1H, J 8.4 Hz, ArH), 7.90 (dd, 1H, J 1.6, 8.8 Hz, ArH), 7.66–7.75 (m, 2H, ArH), 4.44 (d, 1H, J 9.2 Hz, H-1), 3.87 (dd, 1H, J 4.8, 11.2 Hz, H-5e), 3.63–3.67 (m, 1H, H-2), 3.35–3.39 (m, 2H, H-3, H-4), 3.16–3.20 (m, 1H, H-5a); $^{13}\text{C NMR}$ (CD_3OD): δ 137.0, 135.3, 133.5, 132.6, 130.63, 130.59, 130.0, 129.1, 128.8, 125.2, 93.7, 79.1, 71.2, 71.0, 70.2; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_6\text{SNa}^+$ $[\text{M} + \text{Na}]$: 347.0565; found: 347.0557.

5.1.4.7 2-Naphthyl β -L-xylopyranoside (10). Compound **10** was obtained from **35** following the de-O-acetylation method as a white solid (91%). $[\alpha]_D^{21} +38$ (c 0.7, MeOH); $^1\text{H NMR}$ (CD_3OD): δ 7.76–7.80 (m, 3H, ArH), 7.41–7.45 (m, 2H, ArH), 7.35–7.37 (m, 1H, ArH), 7.27 (dd, 1H, J 2.4, 8.8 Hz, ArH), 5.03 (d, 1H, J 7.2 Hz, H-1), 3.97 (dd, 1H, J 5.2, 11.2 Hz, H-5e), 3.58–3.64 (m, 1H, H-4), 4.43–4.53 (m, 3H, H-2, H-3, H-5a); $^{13}\text{C NMR}$ (CD_3OD): δ 156.7, 135.8, 131.3, 130.4, 128.6, 128.1, 127.4, 125.3, 120.0, 111.9, 102.9, 77.8, 74.8, 71.1, 67.0; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_5\text{Na}^+$ $[\text{M} + \text{Na}]$: 299.0895; found: 299.0892.

5.1.4.8 2-Naphthyl α -D-xylopyranoside (11). Compound **11** was obtained from **27** and 2-naphthol using glycosylation method A followed by de-O-acetylation of crude 2-naphthyl 2,3,4-tri-O-acetyl α -D-xylopyranoside as a white solid (33%). $[\alpha]_D^{22} +181$ (c 0.2, MeOH). $^1\text{H-NMR}$ (CD_3OD) δ 7.73–7.880 (m, 3H, ArH), 7.50 (d, 1H, J 2.4 Hz, ArH), 7.40–7.44 (m, 1H, ArH), 7.30–7.37 (m, 2H, ArH), 5.62 (d, 1H, J 3.6 Hz, H-1), 3.84–3.88 (m, 1H H-3), 3.59–3.67 (m, 4H, H-2, H-4, H-5a, H-5e); $^{13}\text{C NMR}$ (CD_3OD) δ 156.1, 135.9, 131.2, 130.4, 128.6, 128.1, 127.4, 125.2, 120.1, 111.9, 99.1, 75.2, 73.4, 71.4, 63.7; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_5\text{Na}^+$ $[\text{M} + \text{Na}]$: 299.0895; found: 299.0887.

5.1.4.9 2-(6-Cyano-naphthyl) β -D-xylopyranoside (19). Compound **19** was obtained from **31** following the de-O-acetylation method as a white solid (67%). $[\alpha]_D^{20} -30$ (c 0.9, MeOH), $^1\text{H-NMR}$ (CD_3OD) δ 8.28 (s, 1H, ArH), 7.93 (d, 1H, J 2.0 Hz, ArH), 7.91 (s, 1H, ArH), 7.60 (dd, 1H, J 1.6, 8.4 Hz, ArH), 7.50 (d, 1H, J 2.0 Hz, ArH), 7.39 (dd, 1H, J 2.4, 9.2 Hz, ArH), 5.10 (d, 1H, J 7.2 Hz, H-1), 3.98 (dd, 1H, J 5.2, 11.2 Hz, H-5e), 3.59–3.62 (m, 1H, H-4), 3.46–3.55 (m, 3H, H-2, H-3, H-5a); $^{13}\text{C-NMR}$ (CD_3OD) δ 159.1, 137.6, 135.0, 131.3, 129.9, 129.6, 127.9, 121.8, 120.3, 111.6, 108.3, 102.4, 77.6, 74.7, 71.0, 67.0; HRMS calcd for $\text{C}_{16}\text{H}_{15}\text{NO}_5\text{Na}^+$ $[\text{M} + \text{Na}]$: 324.0848; found: 324.0849.

5.1.4.10 2-Naphthyl 1-thio- α -L-arabinopyranoside (23). Compound **23** was obtained from **38** following the de-O-acetylation method as a white solid (95%). $[\alpha]_D^{21} -48$ (c 1, MeOH); $^1\text{H NMR}$ (CD_3OD): δ 8.01 (d, 1H, J 1.2 Hz, ArH), 7.78–7.83 (m, 3H, ArH), 7.60 (dd, 1H, J 1.8, 8.6 Hz, ArH), 7.43–7.50 (m, 2H, ArH), 4.77 (d, 1H, J 8.4 Hz, H-1), 4.02 (dd, 1H, J 3.6, 12.4 Hz, H-5a), 3.90–3.92 (m, 1H, H-4), 3.75 (t, 1H, J 8.2 Hz, H-2), 3.60–3.65 (m, 2H, H-5e, H-3); $^{13}\text{C NMR}$ (CD_3OD): δ 135.1, 133.8, 133.6, 130.9, 130.0, 129.3, 128.7, 128.4, 127.5, 127.1, 90.2, 75.0, 71.6, 69.6, 69.5; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_4\text{SNa}^+$ $[\text{M} + \text{Na}]$: 315.0667; found: 315.0659.

5.1.4.11 α -L-Arabinopyranosyl 2-naphthyl sulfone (24). Compound **24** was obtained from **39** following the de-O-acetylation method as a white solid (45%). $[\alpha]_D^{21} +2$ (c 0.9, DMSO); $^1\text{H NMR}$ ($(\text{CD}_3)_2\text{SO}$): δ 8.54 (s, 1H, ArH), 8.20 (d, 1H, J 8.0 Hz, ArH), 8.14 (d, 1H, J 8.8 Hz, ArH), 8.08 (d, 1H, J 8.0 Hz, ArH), 7.87 (dd, 1H, J 1.6, 8.4 Hz, ArH), 7.73–7.77 (m, 1H, ArH), 7.68–7.71 (m, 1H, ArH), 5.31 (d, 1H, J 6.0 Hz, OH), 4.97 (d, 1H, J 6.0 Hz, OH), 4.64 (d, 1H, J 2.0 Hz, OH), 4.44 (d, 1H, J 8.8 Hz, H-1), 3.76–3.82 (m, 1H, H-2), 3.72 (dd, 1H, J 2.0, 12 Hz, H-5a), 3.62 (s, 1H, H-4), 3.49 (d, 1H, J 11.6 Hz, H-5e) 3.41–3.43 (m, 1H, H-3); $^{13}\text{C NMR}$ ($(\text{CD}_3)_2\text{SO}$): δ 135.0, 134.8, 131.6, 130.6, 129.5, 129.3, 128.7, 127.9, 127.6, 124.1, 92.6, 73.2, 70.5, 67.7, 66.7; HRMS calcd for $\text{C}_{15}\text{H}_{16}\text{O}_6\text{SNa}^+$ $[\text{M} + \text{Na}]$: 347.0565; found: 347.0557.

5.1.4.12 (2-Naphthyl)-methyl α -L-arabinopyranoside (25). Compound **25** was obtained from **40** following the de-O-acetylation method as a white solid (90%). $[\alpha]_D^{21} -20$ (c 0.7, MeOH); $^1\text{H NMR}$ (CD_3OD): δ 7.88 (s, 1H, ArH), 7.82–7.85 (m, 3H, ArH), 7.54 (dd, 1H, J 1.6, 8.4 Hz, ArH), 7.44–7.49 (m, 2H, ArH), 5.02 (d, 1H, J 12.4 Hz, CH_2), 4.79 (d, 1H, J 12.0 Hz, CH_2), 4.35 (d, 1H, J 6.8 Hz, H-1), 3.92 (dd, 1H, J 3.2, 12.4 Hz, H-5a), 3.82–3.84 (m, 1H, H-4), 3.66 (dd, 1H, J 6.8, 8.8 Hz, H-2), 3.57 (dd, 1H, J 1.6, 12.4 Hz, H-5e), 3.53 (dd, 1H, J 3.4, 9 Hz, H-3); $^{13}\text{C NMR}$ (CD_3OD): δ 136.6, 134.8, 134.5, 129.0, 128.9, 128.7, 127.7, 127.13, 127.09, 126.9, 103.9, 74.3, 72.5, 71.6, 69.7, 66.9; HRMS calcd for $\text{C}_{16}\text{H}_{18}\text{O}_5\text{Na}^+$ $[\text{M} + \text{Na}]$: 313.1052; found: 313.1054.

5.1.4.13 5-(2-Naphthoxy)-3-oxo-1-pentyl α -L-arabinopyranoside (26). Compound **26** was obtained from **43** following the de-O-acetylation method as a white solid (83%). $[\alpha]_D^{21} +9$ (c 0.9, MeOH); $^1\text{H NMR}$ (CD_3OD): δ 7.74–7.76 (m, 3H, ArH), 7.39–7.43 (m, 1H, ArH), 7.29–7.33 (m, 1H, ArH), 7.24 (d, 1H, J 2.8 Hz, ArH), 7.16 (dd, 1H, J 2.4, 8.8 Hz, ArH), 4.24–4.26 (m, 3H, H-1, CH_2), 3.96–4.01 (m, 1H, CH_2), 3.92–3.95 (m, 2H, CH_2), 3.86 (dd, 1H, J 2.8, 12.4 Hz, H-5a), 3.72–3.81 (m, 4H, H-4, CH_2), 3.58 (dd, 1H, J 6.8, 8.8 Hz, H-2), 4.50–4.54 (m, 2H, H-5e, H-3);



^{13}C NMR (CD_3OD): δ 158.1, 136.1, 130.6, 130.4, 128.6, 127.9, 127.3, 124.7, 119.8, 107.7, 105.0, 74.2, 72.4, 71.7, 70.9, 69.6, 69.4, 68.5, 66.9; HRMS calcd for $\text{C}_{19}\text{H}_{24}\text{O}_7\text{Na}^+$ [$\text{M} + \text{Na}$]: 387.1420; found: 387.1415.

5.1.4.14 1-Naphthyl 2,3,4-tri-O-acetyl- β -D-xylopyranoside (29). Compound 29 was obtained from 27 and 1-naphthol following glycosylation method A as a white solid (75%). $^1\text{H-NMR}$ (CDCl_3) δ 8.13–8.15 (m, 1H, ArH), 7.81–7.83 (m, 1H, ArH), 7.55 (d, 1H, J 8.0 Hz, ArH), 7.46–7.52 (m, 2H, ArH), 7.38 (t, 1H, J 7.6 Hz, ArH), 7.07 (d, 1H, J 7.6 Hz, ArH), 5.29–5.41 (m, 2H, H-1, H-2), 5.31 (t, 1H, J 7.2 Hz, H-3), 5.04–5.09 (m, 1H, H-4), 4.28 (dd, 1H, J 4.8, 12.4 Hz, H-5e), 3.60 (dd, 1H, J 7.6, 12.0 Hz, H-5a), 2.15, 2.11, 2.08 (s, 3H each, OAc); $^{13}\text{C-NMR}$ (CDCl_3) δ 170.0, 170.0, 169.7, 152.5, 134.6, 127.7, 126.7, 126.0, 125.9, 125.8, 122.8, 121.8, 108.9, 98.8, 70.6, 70.1, 68.6, 62.0, 21.0, 21.0, 20.9; HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{O}_8\text{Na}^+$ [$\text{M} + \text{Na}$]: 425.1212; found: 425.1211.

5.1.4.15 4-Phenylphenyl 2,3,4-tri-O-acetyl- β -D-xylopyranoside (30). Compound 30 was obtained from 27 and 4-phenylphenol following glycosylation method A as a white solid (72%). $^1\text{H-NMR}$ (CDCl_3) δ 7.51–7.55 (m, 4H, ArH), 7.42 (t, 2H, J 7.2 Hz, ArH), 7.32 (t, 1H, J 7.4 Hz, ArH), 7.06–7.10 (m, 2H, ArH), 5.21–5.29 (m, 3H, H-1, H-2, H-3), 5.02–5.07 (m, 1H, H-4), 4.25 (dd, 1H, J 4.4, 12.4 Hz, H-5e), 3.55 (dd, 1H, J 7.6, 12.0 Hz, H-5a), 2.10, 2.10, 2.09 (s, 3H each, OAc); $^{13}\text{C-NMR}$ (CDCl_3) δ 170.0, 169.9, 169.4, 156.1, 140.5, 136.2, 128.8, 128.3, 127.1, 126.9, 117.1, 98.5, 70.8, 70.2, 68.5, 61.9, 20.8, 20.8, 20.7; HRMS calcd for $\text{C}_{23}\text{H}_{24}\text{O}_8\text{Na}^+$ [$\text{M} + \text{Na}$]: 451.1369; found: 451.1367.

5.1.4.16 2-(6-Cyano-naphthyl) 2,3,4-tri-O-acetyl- β -D-xylopyranoside (31). Compound 31 was obtained from 27 and 6-cyano-2-naphthol following glycosylation method A as a white solid (33%). $^1\text{H-NMR}$ (CDCl_3) δ 8.15 (s, 1H, ArH), 7.82 (d, 1H, J 13.6 Hz, ArH), 7.80 (d, 1H, J 13.2 Hz, ArH), 7.57 (dd, 1H, J 1.6, 8.4 Hz, ArH), 7.37 (d, 1H, J 2.4 Hz, ArH), 7.28 (dd, 1H, J 2.8, 9.2 Hz, ArH), 5.40 (d, 1H, J 5.2 Hz, H-1), 5.21–5.28 (m, 2H, H-2, H-3), 5.01–5.04 (m, 1H, H-4), 4.27 (dd, 1H, J 4.4, 12.0 Hz, H-5e), 3.49 (dd, 1H, J 6.8, 12.4 Hz, H-5a), 2.11, 2.10, 2.10 (s, 3H each, OAc); $^{13}\text{C-NMR}$ (CDCl_3) δ 169.9, 169.9, 169.5, 156.6, 136.0, 133.9, 130.5, 128.7, 128.4, 127.3, 120.6, 119.4, 110.9, 108.0, 97.9, 70.1, 69.7, 68.3, 61.9, 20.9, 20.9, 20.8; HRMS calcd for $\text{C}_{22}\text{H}_{21}\text{NO}_8\text{Na}^+$ [$\text{M} + \text{Na}$]: 450.1165; found: 450.1163.

5.1.4.17 2-Naphthyl 2,3,4-tri-O-acetyl-1-thio- β -D-xylopyranoside (32). $\text{BF}_3 \cdot \text{OEt}_2$ (1.0 mL, 7.9 mmol) was added to a stirred solution of 2-naphthalenethiol (766 mg, 4.78 mmol) and 1,2,3,4-tetra-O-acetyl- β -D-xylopyranose 27 (1.01 g, 3.19 mmol) in CH_2Cl_2 (3 mL) at rt. The reaction was performed as for glycosylation method A yielding 32 as a white solid (1.05 g, 79%). $^1\text{H-NMR}$ (CDCl_3) δ 7.98 (d, 1H, J 1.6 Hz, ArH), 7.78–7.83 (m, 3H, ArH), 7.54 (dd, 1H, J 2.0, 8.8 Hz, ArH), 7.47–7.51 (m, 2H, ArH), 5.20 (t, 1H, J 8.0 Hz, H-3), 5.00 (t, 1H, J 8.0 Hz, H-2), 4.90–4.96 (m, 2H, H-1, H-4), 4.32 (dd, 1H, J 5.2, 12.0 Hz, H-5e), 3.45 (dd, 1H, J 8.8, 12.0 Hz, H-5a), 2.12, 2.06, 2.05 (s, 3H each, OAc); $^{13}\text{C-NMR}$ (CDCl_3) δ 170.0, 169.9, 169.5, 133.6, 132.9, 132.2, 129.9, 129.6, 128.8, 127.8, 126.8, 86.4, 71.9, 70.0, 68.5, 65.2, 21.0, 20.9; HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{O}_7\text{SNa}^+$ [$\text{M} + \text{Na}$]: 441.0984; found: 441.0980.

5.1.4.18 2-Naphthyl 2,3,4-tri-O-acetyl β -D-xylopyranosyl sulfone (33). Compound 33 was obtained from 32 following the oxidation method as a white solid (91%). $[\alpha]_{\text{D}}^{21} -81$ (c 0.8, CHCl_3); $^1\text{H NMR}$ (CDCl_3): δ 8.50 (s, 1H, ArH), 8.05 (d, 1H, J 8 Hz, ArH), 8.01 (d, 1H, J 8.8 Hz, ArH), 7.96 (d, 1H, J 8 Hz, ArH), 7.87 (dd, 1H, J 1.8, 8.6 Hz, ArH), 7.72 (dt, 1H, J 1.2, 7.6 Hz, ArH), 7.66 (dt, 1H, J 1.4, 7.6 Hz, ArH), 5.30 (m, 1H, H-2), 5.25 (t, 1H, J 8.8 Hz, H-3), 4.77–4.83 (m, 1H, H-4), 4.55 (d, 1H, J 9.2 Hz, H-1), 4.21 (dd, 1H, J 5.2, 11.6 Hz, H-5e), 3.37 (dd, 1H, J 9.6, 11.6 Hz, H-5a), 2.13, 2.01, 1.99 (s, 3H each, OAc); $^{13}\text{C NMR}$ (CDCl_3): δ 170.2, 169.8, 169.6, 135.9, 132.8, 132.1, 132.0, 130.0, 129.9, 129.3, 128.1, 127.8, 124.5, 90.0, 72.7, 68.3, 67.0, 66.9, 20.9, 20.7; HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{O}_9\text{SNa}^+$ [$\text{M} + \text{Na}$]: 473.0882; found: 473.0879.

5.1.4.19 2-Naphthyl 2,3,4-tri-O-acetyl β -L-xylopyranoside (35). Compound 35 was obtained from 34 and 2-naphthol following glycosylation method A as a white solid (78%). $[\alpha]_{\text{D}}^{21} +28$ (c 0.9, CHCl_3); $^1\text{H NMR}$ (CDCl_3): δ 7.73–7.80 (m, 3H, ArH), 7.44–7.48 (m, 1H, ArH), 7.36–7.41 (m, 2H, ArH), 7.18 (dd, 1H, J 2.4, 8.8 Hz, ArH), 5.34 (d, 1H, J 6.0 Hz, H-1), 5.22–5.35 (m, 2H, H-3, H-2), 5.02–5.07 (m, 1H, H-4), 4.28 (dd, 1H, J 4.6, 12.2 Hz, H-5e), 3.60 (dd, 1H, J 7.6, 12 Hz, H-5a), 2.113, 2.105, 2.10 (s, 3H each, OAc); $^{13}\text{C NMR}$ (CDCl_3): δ 170.1, 170.0, 169.6, 154.5, 134.3, 130.2, 129.8, 127.8, 127.3, 126.7, 124.8, 118.9, 111.4, 98.7, 70.7, 70.2, 68.6, 62.0, 21.0, 20.93, 20.90; HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{O}_8\text{Na}^+$ [$\text{M} + \text{Na}$]: 425.1212; found: 425.1202.

5.1.4.20 2-Naphthyl 2,3,4-tri-O-acetyl 1-thio- α -L-arabinopyranoside (38). Arabinopyranosyl bromide 37¹⁸ (330 mg) was dissolved in EtOAc (3.3 mL) and 2-naphthalenethiol (334 mg, 2.08 mmol), TBAHS (tetrabutylammonium hydrogen sulfate) (532 mg, 1.57 mmol), and aqueous Na_2CO_3 (1 M, 3.3 mL) were added. After 12 h, the reaction mixture was diluted with EtOAc (15 mL) and washed with satd aq. Na_2CO_3 (2 \times 20 mL), brine (20 mL), and water (20 mL). The organic phase was dried before removal of solvent under reduced pressure. Column chromatography (SiO_2 , 10 \rightarrow 30% EtOAc in heptane) gave 38 as a white solid (262 mg, 39% over 3 steps from L-arabinose). $[\alpha]_{\text{D}}^{21} +5$ (c 1, CHCl_3); $^1\text{H NMR}$ (CDCl_3): δ 8.01 (d, 1H, J 2 Hz, ArH), 7.78–7.83 (m, 3H, ArH), 7.56 (dd, 1H, J 1.8, 8.6 Hz, ArH), 7.47–7.52 (m, 2H, ArH), 5.28–5.32 (m, 2H, H-2, H-4), 5.14 (dd, 1H, J 3.4, 8.2 Hz, H-3), 4.92 (d, 1H, J 7.6 Hz, H-1), 4.20 (dd, 1H, J 4.4, 12.4 Hz, H-5a), 3.71 (dd, 1H, J 2.0, 12.8 Hz, H-5e), 2.13, 2.09, 2.07 (s, 3H each, OAc); $^{13}\text{C NMR}$ (CDCl_3): δ 170.4, 170.1, 169.6, 133.6, 132.8, 131.7, 130.6, 129.6, 128.7, 127.9, 127.8, 126.8, 126.7, 87.1, 70.6, 68.7, 67.6, 65.4, 21.0, 20.9; HRMS calcd for $\text{C}_{21}\text{H}_{22}\text{O}_7\text{SNa}^+$ [$\text{M} + \text{Na}$]: 441.0984; found: 441.0977.

5.1.4.21 2-Naphthyl 2,3,4-tri-O-acetyl α -L-arabinopyranosyl sulfone (39). Compound 39 was obtained from 38 following the oxidation method as a white solid (96%). $[\alpha]_{\text{D}}^{21} -44$ (c 1, DMSO); $^1\text{H NMR}$ (CDCl_3): δ 8.56 (s, 1H, ArH), 8.06 (d, 1H, J 8.0 Hz, ArH), 8.01 (d, 1H, J 8.8 Hz, ArH), 7.93 (m, 2H, ArH), 7.72 (dt, 1H, J 1.3, 7.5 Hz, ArH), 7.64 (dt, 1H, J 1.3, 7.5 Hz, ArH), 5.53 (t, 1H, J 9.4 Hz, H-2), 5.13–5.14 (m, 1H, H-4), 5.05 (dd, 1H, J 3.2, 9.6 Hz, H-3), 4.55 (d, 1H, J 9.2 Hz, H-1), 4.10 (dd, 1H, J 2.4, 13.2 Hz, H-5a), 3.68 (dd, 1H, J 1.0, 13 Hz, H-5e), 2.53, 1.99, 1.64 (s, 3H each, OAc); $^{13}\text{C NMR}$ (CDCl_3): δ 170.2, 170.1, 169.6,



135.8, 132.8, 132.2, 132.1, 129.9, 129.8, 128.9, 128.0, 127.7, 124.9, 90.1, 71.0, 67.7, 67.6, 64.6, 21.0, 20.8, 20.4; HRMS calcd for $C_{21}H_{22}O_9Na^+$ [M + Na]: 473.0882; found: 473.0877.

5.1.4.22 (2-Naphthyl)-methyl 2,3,4-tri-O-acetyl α -L-arabinopyranoside (40). Compound **40** was obtained from **37**¹⁸ and 2-naphthalenemethanol following glycosylation method B as a white solid (20% over 3 steps from L-arabinose). ¹H NMR (CDCl₃): δ 7.79–7.83 (m, 3H, ArH), 7.75 (s, 1H, ArH), 7.44–7.49 (m, 2H, ArH), 7.41 (dd, 1H, *J* 1.6, 8.4 Hz, ArH), 5.25–5.31 (m, 2H, H-2, H-4), 4.99–5.05 (m, 2H, H-3, CH₂), 4.75 (d, 1H, *J* 12.4 Hz, CH₂), 4.52 (d, 1H, *J* 6.8 Hz, H-1), 4.06 (dd, 1H, *J* 3.4, 13.0 Hz, H-5a), 3.61 (dd, 1H, *J* 1.6, 12.8 Hz, H-5e), 2.13, 2.03, 2.00 (s, 3H each, OAc); ¹³C NMR (CDCl₃): δ 170.3, 170.1, 169.4, 134.4, 133.1, 133.0, 128.2, 127.8, 127.7, 126.5, 126.3, 126.1, 125.5, 99.4, 70.4, 70.1, 69.2, 67.6, 63.0, 20.9, 20.8, 20.7; HRMS calcd for $C_{22}H_{24}O_8Na^+$ [M + Na]: 439.1369; found: 439.1361.

5.1.4.23 5-Chloro-3-oxo-1-pentyl 2,3,4-tri-O-acetyl- α -L-arabinopyranoside (42). KOAc (7.90 g, 80.5 mmol) was suspended in acetic anhydride (110 mL) and heated to 130 °C. L-Arabinose **41** (10.0 g, 66.9 mmol) was added in portions over 5 minutes and after 1.5 hours of heating at 130 °C, the reaction mixture was allowed to reach rt before poured onto ice. The aqueous phase was extracted with CH₂Cl₂ (3 × 500 mL) and the combined organic layers were washed with satd aq. NaHCO₃ (1 L), dried, and stirred with activated charcoal. After 30 minutes, the mixture was filtered through silica and concentrated to yield 1,2,3,4-tetra-O-acetyl-L-arabinopyranose as a yellow oil (23.2 g) that was used without further purification. BF₃·Et₂O (1.10 mL, 8.68 mmol) was added to a stirred solution of crude peracetylated L-arabinose (1.09 g) and 2-(2-chloroethoxy)-ethanol (540 μ L, 5.12 mmol) in CH₂Cl₂ (10 mL) at 0 °C. The reaction was performed as for glycosylation method A yielding **42** as a white solid (30% over 2 steps from L-arabinose). ¹H NMR (CDCl₃): δ 5.24–5.26 (m, 1H, H-4), 5.19 (dd, 1H, *J* 7.2, 9.2 Hz, H-2), 5.03 (dd, 1H, *J* 3.6, 9.2 Hz, H-3), 4.52 (d, 1H, *J* 7.2 Hz, H-1), 4.03 (dd, 1H, *J* 3.3, 13.2 Hz, H-5a), 3.92–3.97 (m, 1H, CH₂), 3.59–3.75 (m, 8H, CH₂, H-5e), 2.13, 2.07, 2.01 (s, 3H each, OAc); ¹³C NMR (CDCl₃): δ 170.5, 170.3, 169.7, 101.1, 71.6, 70.5, 70.3, 69.2, 68.8, 67.8, 63.3, 43.0, 21.1, 21.0, 20.8; HRMS calcd for $C_{15}H_{23}ClO_9Na^+$ [M + Na]: 405.0928; found: 405.0919.

5.1.4.24 5-(2-Naphthoxy)-3-oxo-1-pentyl 2,3,4-tri-O-acetyl- α -L-arabinopyranoside (43). 2-Naphthol (127 mg, 0.879 mmol), K₂CO₃ (70 mg, 0.51 mmol), and 18-crown-6 (1.21 g, 4.57 mmol) were stirred in DMF (2 mL) for 1 hour before **42** (166 mg, 0.434 mmol), dissolved in DMF (3 mL), was added. The reaction mixture was heated to 80 °C for 40 hours before it was allowed to reach rt and water (10 mL) was added. The aqueous phase was extracted with EtOAc (3 × 10 mL) and the combined organic phases were washed with brine (50 mL) and dried before removal of solvent under reduced pressure. Column chromatography (SiO₂, 20 → 40% EtOAc in heptane) gave **43** as a light brown solid (85 mg, 40%). ¹H NMR (CDCl₃): δ 7.71–7.77 (m, 3H, ArH), 7.41–7.45 (m, 1H, ArH), 7.31–7.35 (m, 1H, ArH), 7.17 (dd, 1H, *J* 2.4, 8.8 Hz, ArH), 7.14 (d, 1H, *J* 2.4 Hz, ArH), 5.23–5.25 (m, 1H, H-4), 5.21 (dd, 1H, *J* 7.0, 9.4 Hz, H-2), 5.02 (dd, 1H, *J* 3.6, 9.2 Hz, H-3), 4.50 (d, 1H, *J* 6.8 Hz,

H-1), 4.21–4.23 (m, 2H, CH₂), 3.96–4.03 (m, 2H, H-5a, CH₂), 3.88–3.91 (m, 2H, CH₂), 3.73–3.76 (m, 3H, CH₂), 3.58 (dd, 1H, *J* 1.8, 13.0 Hz, H-5e), 2.11, 2.05, 2.01 (s, 3H each, OAc); ¹³C NMR (CDCl₃): δ 170.4, 170.3, 169.6, 156.8, 134.5, 129.5, 129.1, 127.7, 126.8, 126.4, 123.8, 119.0, 106.7, 101.1, 70.6, 70.2, 69.9, 69.2, 68.9, 67.7, 67.5, 63.2, 21.0, 20.8, 20.7; HRMS calcd for $C_{25}H_{30}O_{10}Na^+$ [M + Na]: 513.1737; found: 513.1736.

5.2 β 4GalT7 assay

The β 4GalT7 assay has been described in detail previously.⁴

5.3 GAG priming in cells

The procedures for cell culture, radiolabeling, and isolation of xyloside-primed [³⁵S]sulfate-labeled polyanionic material have been described in detail previously.¹⁴

5.4 Molecular docking simulations of the Michaelis complex

For molecular docking simulations, the protein crystal structure of *Drosophila* β -1,4-Galactosyltransferase 7 mutant D211N in complex with xylobiose, manganese, UDP-galactose, or UDP (PDB ID: 4M4K and 4LW6 respectively) was prepared using Autodock Tools (ADT).⁴⁷ The xylobiose molecule was removed and water molecules were either included or excluded in the docking (*vide supra*). The ligands were built using the gview program (GaussView Version 5, Dennington *et al.*, Semichem Inc., Shawnee Mission, KS, 2009.) and geometry-optimized using the ORCA 2.9.1 package⁴⁸ with the B3LYP functional and a 6-31G* basis set.

The docking simulations were performed using the Autodock VINA 1.1.2 package⁴⁹ using a cubic 24 Å grid, an exhaustiveness of 64 and a random starting seed. Residues deemed to have possible interactions with the naphthyl group, K176, H178, and Y179, were treated as flexible residues. The nine top-scored poses from the docking simulations were analyzed and grouped based on interaction similarities. Subsequently, one representative structure from the major cluster was chosen for each ligand (among the three highest ranked poses in all cases). The selected structures were H-bond optimized and energy minimized employing a 0.6 Å heavy atom restraint (OPLS-2005 force field) with the Protein preparation wizard within the Maestro software.⁵⁰ The resulting geometries were then evaluated.

Acknowledgements

This work was supported by grants from the Alfred Österlund Foundation, the Crafoord Foundation, the Evy and Gunnar Sandberg Foundation, Greta and John Kock, the Gunnar Nilsson Cancer Foundation, the Heart & Lung Foundation, the Knut and Alice Wallenberg Foundation, the Koch Foundation, Lars Hiertas Memorial Foundation, the Magnus Bergwall Foundation, the Medical Faculty of Lund University, Lund University, the Royal Physiographic Society in Lund, Syskonen Svenssons Foundation for Medical Research, the Swedish Cancer Society, the Swedish Medical Research Council (11550), and the Swedish Research Council.



Notes and references

- R. Almeida, S. B. Lavery, U. Mandel, H. Kresse, T. Schwientek, E. P. Bennett and H. Clausen, *J. Biol. Chem.*, 1999, **274**, 26165.
- X. Bai, D. Zhou, J. R. Brown, B. E. Crawford, T. Hennem and J. D. Esko, *J. Biol. Chem.*, 2001, **276**, 48189.
- P. Carlsson and L. Kjellen, *Handbook of Experimental Pharmacology*, 2012, vol. 207, p. 23.
- A. Siegbahn, S. Manner, A. Persson, E. Tykesson, K. Holmqvist, A. Ochocinska, J. Roennols, A. Sundin, K. Mani, G. Westergren-Thorsson, G. Widmalm and U. Ellervik, *Chem. Sci.*, 2014, **5**, 3501.
- M. M. Fuster and J. D. Esko, *Nat. Rev. Cancer*, 2005, **5**, 526.
- M. Belting, L. Borsig, M. M. Fuster, J. R. Brown, L. Persson, L.-A. Fransson and J. D. Esko, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 371.
- K. Mani, M. Belting, U. Ellervik, N. Falk, G. Svensson, S. Sandgren, F. Cheng and L.-A. Fransson, *Glycobiology*, 2004, **14**, 387.
- U. Nilsson, R. Johnsson, L.-A. Fransson, U. Ellervik and K. Mani, *Cancer Res.*, 2010, **70**, 3771.
- K. Descroix and G. K. Wagner, *Org. Biomol. Chem.*, 2011, **9**, 1855.
- T. A. Fritz, F. N. Lugemwa, A. K. Sarkar and J. D. Esko, *J. Biol. Chem.*, 1994, **269**, 300.
- C. T. Bishop and F. P. Cooper, *Can. J. Chem.*, 1962, **40**, 224.
- J. Malmberg, K. Mani, E. Saewen, A. Wiren and U. Ellervik, *Bioorg. Med. Chem.*, 2006, **14**, 6659.
- K. Holmqvist, A. Persson, R. Johnsson, J. Lofgren, K. Mani and U. Ellervik, *Bioorg. Med. Chem.*, 2013, **21**, 3310.
- K. Mani, B. Havsmark, S. Persson, Y. Kaneda, H. Yamamoto, K. Sakurai, S. Ashikari, H. Habuchi, S. Suzuki, K. Kimata, A. Malmstrom, G. Westergren-Thorsson and L.-A. Fransson, *Cancer Res.*, 1998, **58**, 1099.
- C.-O. Abrahamsson, U. Ellervik, J. Eriksson-Bajtner, M. Jacobsson and K. Mani, *Carbohydr. Res.*, 2008, **343**, 1473.
- K. Higashi, H. Hori, T. Ishiyama, Y. Okimoto, I. Kusakabe and T. Yasui, *Agric. Biol. Chem.*, 1983, **47**, 1123.
- A. Siegbahn, U. Aili, A. Ochocinska, M. Olofsson, J. Roennols, K. Mani, G. Widmalm and U. Ellervik, *Bioorg. Med. Chem.*, 2011, **19**, 4114.
- S. C. Timmons and D. L. Jakeman, *Carbohydr. Res.*, 2008, **343**, 865.
- M. Lundborg, E. Ali and G. Widmalm, *Carbohydr. Res.*, 2013, **378**, 133.
- Y. Tsutsui, B. Ramakrishnan and P. K. Qasba, *J. Biol. Chem.*, 2013, **288**, 31963.
- H. C. Robinson, M. J. Brett, P. J. Tralagga, D. A. Lowther and M. Okayama, *Biochem. J.*, 1975, **148**, 25.
- F. N. Lugemwa and J. D. Esko, *J. Biol. Chem.*, 1991, **266**, 6674.
- T. A. Fritz, F. N. Lugemwa, A. K. Sarkar and J. D. Esko, *J. Biol. Chem.*, 1994, **269**, 300.
- A. K. Sarkar, T. A. Fritz, W. H. Taylor and J. D. Esko, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 3323.
- A. Sinha, W. H. Taylor, I. H. Khan, S. T. McDaniel and J. D. Esko, *J. Nat. Prod.*, 1999, **62**, 1036.
- R. Johnsson, K. Mani, F. Cheng and U. Ellervik, *J. Org. Chem.*, 2006, **71**, 3444.
- V. M. Tran, X. V. Victor, J. W. Yockman and B. Kuberan, *Glycoconjugate J.*, 2010, **27**, 625.
- V. M. Tran and B. Kuberan, *Bioconjugate Chem.*, 2014, **25**, 262.
- N. B. Schwartz, L. Galligani, P.-L. Ho and A. Dorfman, *Proc. Natl. Acad. Sci. U. S. A.*, 1974, **71**, 4047.
- N. B. Schwartz and L. Roden, *J. Biol. Chem.*, 1975, **250**, 5200.
- Y. Fukunaga, M. Sobue, N. Suzuki, H. Kushida and S. Suzuki, *Biochim. Biophys. Acta*, 1975, **381**, 443.
- J. A. Robinson and H. C. Robinson, *Biochem. J.*, 1981, **194**, 839.
- S. O. Kolset, K. Sakurai, I. Ivhed, A. Oevervatn and S. Suzuki, *Biochem. J.*, 1990, **265**, 637.
- B. Kuberan, M. Ethirajan, X. V. Victor, V. Tran, K. Nguyen and A. Do, *ChemBioChem*, 2008, **9**, 198.
- M. Sobue, H. Habuchi, K. Ito, H. Yonekura, K. Oguri, K. Sakurai, S. Kamohara, Y. Ueno, R. Noyori and S. Suzuki, *Biochem. J.*, 1987, **241**, 591.
- M. Jacobsson, K. Mani and U. Ellervik, *Bioorg. Med. Chem.*, 2007, **15**, 5283.
- J. Malmberg, K. Mani, E. Sawen, A. Wiren and U. Ellervik, *Bioorg. Med. Chem.*, 2006, **14**, 6659.
- X. V. Victor, T. K. N. Nguyen, M. Ethirajan, V. M. Tran, K. V. Nguyen and B. Kuberan, *J. Biol. Chem.*, 2009, **284**, 25842.
- K. Raman and B. Kuberan, *Mol. BioSyst.*, 2010, **6**, 1800.
- T. K. N. Nguyen, V. M. Tran, V. Sorna, I. Eriksson, A. Kojima, M. Koketsu, D. Loganathan, L. Kjellen, R. I. Dorsky, C.-B. Chien and B. Kuberan, *ACS Chem. Biol.*, 2013, **8**, 939.
- F. M. Menger, *Adv. Chem. Ser.*, 1987, **215**, 209.
- M. Okayama, K. Kimata and S. Suzuki, *J. Biochem.*, 1973, **74**, 1069.
- F. Daligault, S. Rahuel-clermont, S. Gulberti, M.-T. Cung, G. Branlant, P. Netter, J. Magdalou and V. Lattard, *Biochem. J.*, 2009, **418**, 605.
- R. L. Stevens and K. F. Austen, *J. Biol. Chem.*, 1982, **257**, 253.
- M. Jacobsson, U. Ellervik, M. Belting and K. Mani, *J. Med. Chem.*, 2006, **49**, 1932.
- S. Gulberti, V. Lattard, M. Fondeur, J.-C. Jacquinet, G. Mulliert, P. Netter, J. Magdalou, M. Ouzzine and S. Fournel-Gigleux, *J. Biol. Chem.*, 2005, **280**, 1417.
- M. Morris Garrett, R. Huey, W. Lindstrom, F. Sanner Michel, K. Belew Richard, S. Goodsell David and J. Olson Arthur, *J. Comput. Chem.*, 2009, **30**, 2785.
- F. Neese, *Wiley Interdiscip. Rev.: Comput. Mol. Sci.*, 2012, **2**, 73.
- O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455.
- Schrödinger Release 2014-3: Maestro, version 9.9*, LLC, Schrödinger, New York, NY, 2014.

